Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF10' education - Sep. 26, 2023 - Aaron Wong, MD - Bridgend, Wales, UK
Video navigation menu
- RAASi therapy is the cornerstone treatment for HF, CKD and T2D 00:22
- Suboptimal RAASi therapy following a hyperkalemic event 01:33
- Practical experience with SZC for the optimization of RAASi in HFrEF 02:44
- Model for the prescribing and monitoring of SZC in HF therapy 06:38
- Conclusions 08:24
This lecture by Aaron Wong, MD was part of the EBAC-accredited symposium "Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy" held at the ESC Congress 2023, Amsterdam, The Netherlands.
Aaron Wong, MD is a consultant cardiologist and general physician working at the Princess of Wales Hospital, Bridgend, South Wales, United Kingdom. He is the local heart failure lead, and also works as a local principal investigator.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.